<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00454376</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000537344</org_study_id>
    <secondary_id>EORTC-QLQ-G.I.NET21</secondary_id>
    <secondary_id>EU-20712</secondary_id>
    <secondary_id>BNHFT-P4NET</secondary_id>
    <secondary_id>EU-207101</secondary_id>
    <nct_id>NCT00454376</nct_id>
  </id_info>
  <brief_title>Disease-Specific Questionnaire in Assessing Quality of Life in Patients With Gastrointestinal-Related Neuroendocrine Tumors</brief_title>
  <official_title>Clinical and Psychometric Validation of a Disease-Specific Questionnaire Module in Assessing the Quality of Life of Patients With G.I.-Related Neuroendocrine Tumours</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Questionnaires that measure quality of life may help doctors identify the effects
      of treatment and improve the ability to plan treatment for patients with
      gastrointestinal-related neuroendocrine tumors.

      PURPOSE: This phase IV clinical trial is studying how well a disease-specific questionnaire
      works in assessing the quality of life of patients with gastrointestinal-related
      neuroendocrine tumors.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

      Primary

        -  Test the scale structure, reliability, and validity of the gastrointestinal
           neuroendocrine tumor module (QLQ-G.I.NET21) in patients with gastrointestinal-related
           neuroendocrine tumors.

      Secondary

        -  Determine the quality of life of patients using QLQ-C30 and the QLQ-G.I.NET21 before and
           after treatment.

      OUTLINE: This is a multicenter study. Patients are stratified according to treatment
      (somatostatin analogue therapy or interferon therapy vs radionuclide therapy or chemotherapy
      vs ablative therapies [embolization or radiofrequency ablation] or liver resection).

      Patients complete the EORTC C30 questionnaire, QLQ-G.I.NET21 module, and are evaluated for
      Karnofsky performance status at pretreatment, at 3 and 6 months after treatment, and then 2
      weeks later. Patients also complete a clinical data and sociodemographic data form and
      debriefing questionnaire at pretreatment; a follow-up form at 3 months and 6 months after
      treatment; and a test-retest form 2 weeks later.

      PROJECTED ACCRUAL: A total of 408 patients will be accrued for this study.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>October 2006</start_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <primary_outcome>
    <measure>Reliability, scaling, scale correlation, and clinical validity of the gastrointestinal neuroendocrine tumor module (QLQ-G.I.NET21)</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Response to change after various treatments</measure>
  </secondary_outcome>
  <enrollment type="Anticipated">408</enrollment>
  <condition>Gastrointestinal Carcinoid Tumor</condition>
  <condition>Islet Cell Tumor</condition>
  <condition>Lung Cancer</condition>
  <condition>Metastatic Cancer</condition>
  <condition>Neoplastic Syndrome</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>questionnaire administration</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>quality-of-life assessment</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Histologically confirmed neuroendocrine tumor OR characteristic radiological findings
             of neuroendocrine tumor with raised hormone levels in plasma or urine meeting any of
             the following criteria:

               -  Primary disease in gut with liver metastases (with or without hormone secretion)

               -  Primary disease in lung with liver or abdominal metastases (with or without
                  hormone secretion)

               -  Primary disease in pancreas with or without metastases (with or without hormone
                  secretion)

        PATIENT CHARACTERISTICS:

          -  Any Karnofsky performance status allowed

          -  Life expectancy â‰¥ 3 months

          -  Able to understand the questionnaire language

          -  Mentally fit to complete questionnaire

          -  No psychological, familial, sociological, or geographical condition that would limit
             study compliance

          -  No other concurrent malignancies except basal cell carcinoma of the skin

        PRIOR CONCURRENT THERAPY:

          -  More than 2 months since prior somatostatin analogue or interferon therapy
             (somatostatin therapy stratum)

               -  Concurrent somatostatin analogue and/or interferon therapy allowed if dose stable
                  over the past month

          -  More than 6 months since prior radionuclide therapy or systemic chemotherapy
             (radionuclide or systemic chemotherapy stratum)

          -  More than 6 months since prior ablative therapies (ablative therapy stratum)

          -  No concurrent participation in other quality of life studies
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John K. Ramage, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Basingstoke and North Hampshire NHS Foundation Trust</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Aarhus Universitetshospital - Aarhus Sygehus</name>
      <address>
        <city>Aarhus</city>
        <zip>DK 8000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charite - Campus Charite Mitte</name>
      <address>
        <city>Berlin</city>
        <zip>D-10117</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum der Universitaet Regensburg</name>
      <address>
        <city>Regensburg</city>
        <zip>D-93053</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Athens Alexandras Hospital</name>
      <address>
        <city>Athens</city>
        <zip>611</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hadassah University Hospital</name>
      <address>
        <city>Jerusalem</city>
        <zip>91120</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical and Experimental Medicine at the University of Verona</name>
      <address>
        <city>Verona</city>
        <zip>37129</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital</name>
      <address>
        <city>Amsterdam</city>
        <zip>1066 CX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology - Warsaw</name>
      <address>
        <city>Warsaw</city>
        <zip>02-781</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario San Carlos</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Uppsala University Hospital</name>
      <address>
        <city>Uppsala</city>
        <zip>SE-75185</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Basingstoke and North Hampshire NHS Foundation Trust</name>
      <address>
        <city>Basingstoke</city>
        <state>England</state>
        <zip>RG24 9NA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aintree University Hospital</name>
      <address>
        <city>Liverpool</city>
        <state>England</state>
        <zip>L9 7AL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UCL Cancer Institute</name>
      <address>
        <city>London</city>
        <state>England</state>
        <zip>NW1 2QG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>King's College Hospital</name>
      <address>
        <city>London</city>
        <state>England</state>
        <zip>SE5 9RS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southampton General Hospital</name>
      <address>
        <city>Southampton</city>
        <state>England</state>
        <zip>SO16 6YD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Victoria Hospital</name>
      <address>
        <city>Belfast</city>
        <state>Northern Ireland</state>
        <zip>BT12 6BA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
    <country>Germany</country>
    <country>Greece</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Poland</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>United Kingdom</country>
  </location_countries>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>November 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 27, 2007</study_first_submitted>
  <study_first_submitted_qc>March 27, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 30, 2007</study_first_posted>
  <last_update_submitted>October 28, 2013</last_update_submitted>
  <last_update_submitted_qc>October 28, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 29, 2013</last_update_posted>
  <keyword>metastatic gastrointestinal carcinoid tumor</keyword>
  <keyword>recurrent gastrointestinal carcinoid tumor</keyword>
  <keyword>pulmonary carcinoid tumor</keyword>
  <keyword>gastrinoma</keyword>
  <keyword>insulinoma</keyword>
  <keyword>WDHA syndrome</keyword>
  <keyword>pancreatic polypeptide tumor</keyword>
  <keyword>somatostatinoma</keyword>
  <keyword>glucagonoma</keyword>
  <keyword>liver metastases</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Neuroendocrine Tumors</mesh_term>
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Carcinoid Tumor</mesh_term>
    <mesh_term>Malignant Carcinoid Syndrome</mesh_term>
    <mesh_term>Gastrointestinal Neoplasms</mesh_term>
    <mesh_term>Adenoma, Islet Cell</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

